Vyzulta sales boost Nicox’s quarterly revenue

Nicox reported cash and cash equivalents of 32.6 million euros at the end of the second quarter of 2018, down from 36.3 million euros in the first quarter, according to a company press release.

Net revenue for the quarter was 0.226 million euros, entirely comprised of royalties from sales of Vyzulta by global partner Bausch + Lomb. In the same quarter of 2017, Nicox recorded no revenue.

A research agreement with Ironwood Pharmaceuticals was announced in June, in which the two companies will work together to generate novel compounds intended to treat certain ophthalmic conditions using Ironwood’s soluble guanylate cyclase and Nicox’s nitric oxide-donating research platform, according to the release.

Nicox reported cash and cash equivalents of 32.6 million euros at the end of the second quarter of 2018, down from 36.3 million euros in the first quarter, according to a company press release.

Net revenue for the quarter was 0.226 million euros, entirely comprised of royalties from sales of Vyzulta by global partner Bausch + Lomb. In the same quarter of 2017, Nicox recorded no revenue.

A research agreement with Ironwood Pharmaceuticals was announced in June, in which the two companies will work together to generate novel compounds intended to treat certain ophthalmic conditions using Ironwood’s soluble guanylate cyclase and Nicox’s nitric oxide-donating research platform, according to the release.